Abivax S.A.
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 3 days.
- Recent price momentum is -39.3% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 4.7% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability F
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | -122,456.5% | Better than 0% |
| Operating margin | -144,760.9% | Better than 0% |
| Net margin | -133,191.3% | Better than 0% |
| Return on equity | -135.6% | Better than 4% |
| Return on invested capital | -107.2% | Better than 2% |
Momentum D
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -36.3% | Better than 13% |
| 6-month return | -40.0% | Better than 12% |
| 12-month return (ex latest month) | -24.3% | Better than 12% |
| Distance below 52-week high | 50.8% | Better than 18% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 8.7x | Better than 92% |
| Debt to assets | 0.3% | Better than 97% |
| Interest coverage | -10.6x | Better than 13% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 88.9% | Better than 72% |
| Upside to average target | 119.3% | Better than 87% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 80.65
- Open
- 79.01
- Day range
- 62.70 - 79.74
- Avg price
- 70.52
- Volume
- 14.85M
- Turnover
- 1.05B
- Turnover ratei
- 19.11%
- Volume ratioi
- 11.52
- Amplitudei
- 21.12%
- 52-week rangei
- 62.70 - 148.83
Valuation
- P/Ei
- -13.82
- P/E (TTM)i
- -12.52
- P/Bi
- 15.95
- EPSi
- -5.30
- Book value / shi
- 4.59
- Net profit
- -463.71M
- Net assets
- 401.64M
Share structure
- Market cap
- 6.41B
- Float capi
- 5.69B
- Shares out
- 87.54M
- Float sharesi
- 77.74M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2023-10-20
50.8% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-43.45M net over the window
Short interest
- Shares short
- 4.11M
- % of floati
- 4.70%
- Days to coveri
- 4.63
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Abivax S.A. (ABVX)?
Abivax S.A. last traded at 73.20. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Abivax S.A.'s market cap?
About 6.41B.
What is the P/E ratio of Abivax S.A.?
The trailing twelve-month P/E is -12.52. The Valuation tab shows it against the stock's own five-year range.
Does Abivax S.A. pay a dividend?
Abivax S.A. does not currently pay a regular dividend.
Is Abivax S.A. a buy according to analysts?
The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 160.56, which implies 119.3% upside from the current price. This is not investment advice.
What is Abivax S.A.'s StockVane Quant Rating?
The StockVane Momentum strategy currently rates Abivax S.A. a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 20:02:37 · For reference only, not investment advice and not tailored to your situation.
Abivax S.A. discussion 0 comments